Efficacy and safety of short-acting anticholinergics in patients with acute exacerbation of chronic obstructive pulmonary disease receiving maintenance therapy with tiotropium
https://doi.org/10.18093/0869-0189-2008-0-1-62-68
Abstract
The aim of the study was to assess efficacy and safety of ipratropium and ipratropium/fenoterol in patients with acute exacerbation of COPD receiving maintenance therapy with tiotropium. Design: prospective, randomized, controlled cross-over study. Patients and methods. Thirty six patients with COPD exacerbation (mean age 66 yrs; mean FEV1 26 %) were included in the study. Patients were randomized to receive either ipratropium or ipratropium/fenoterol on two different test days. The study consisted of two different protocols. In the 1st protocol, the patients received either nebulized solution of ipratropium 500 μg or ipratropium/fenoterol 500/1000 μg. In the 2nd protocol, patients received either ipratropium 80 μg via metered dose inhaler (MDI) and spacer or ipratropium/fenoterol 80/200 μg. Spirometry, clinical and hemodynamic measurements were performed immediately before and at 1 and 4 hours after inhalation of ipratropium or ipratropium/fenoterol. Nebulized therapy with ipratropium or ipratropium/fenoterol resulted in statistically and clinically significant improvement in FEV1 , FVC and IC at 1 and 4 hours after inhalation (р < 0.01). In terms of the bronchodilator effect, add-on therapy with ipratropium/fenoterol was nonsignificantly superior to add-on ipratropium. There were no serious adverse events after inhaled therapy including hemodynamic parameters (BP, ECG, QTc). Only ipratropium/fenoterol resulted in increase of heart rate, approximately by 3.8 beats per minute (bpm) at 1 hour after inhalation (p < 0.001). Inhaled therapy with ipratropium or ipratropium/fenoterol via MDI and spacer led to similar results as nebulized therapy. Heart rate was increased at 1 hour after inhalation of ipratropium/fenoterol via MDI and spacer by 3.7 bpm (p < 0.001). In patients with acute exacerbation of COPD receiving maintenance therapy with tiotropium, the addition of ipratropium or ipratropium / fenoterol provides significant bronchodilator effect without any serious adverse events.
About the Authors
S. N. Avdeev
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
G. S. Nuralieva
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
A. G. Chuchalin
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2006. www.goldcopd.org.
2. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir. J. 2003; 21 (suppl. 41): 46s–53s.
3. Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med. 2006; 5: 343–349.
4. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
5. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.
6. Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–1455.
7. Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. J. A. M. A. 1995; 274: 1852–1857.
8. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.
9. Rodriguez)Roisin R. COPD exacerbations: Management. Thorax 2006; 61: 535–544.
10. Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких: Практическое руководство для врачей. М.; 2004.
11. Celli B.R., MacNee W., committee members of ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
12. van der Woude H.J., Winter T.H., Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β 2 agonists. Thorax 2001; 56: 529–535.
13. Lipworth B.J., Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; 117: 156–162.
14. Cooper C.B., Tashkin D.P. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. Brit. Med. J. 2005; 330: 640–644.
15. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
16. Quanjer Ph.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (suppl. 16): 5–40.
17. Borg G.A.V. Psychophysical basis of perceived exertion. Med. Sci. Sports Exerc. 1982; 14: 377–381.
18. Kautzener J. QT interval measurements. Card Electrophysiolol Rev. 2002; 6: 273–277.
19. Di Marco F., Verga M., Santus P. et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: A pilot study. Respir. Med. 2006; 100: 1925–1932.
20. Koenen)Bergmann M., Witek J., Tuerck D. et al. Pharmacologic effects of acute administration of ipratropium on top of maintenance treatment with tiotropium. Eur. Respir. J. 2003; 22 (suppl. 45): 67S.
21. Kerstjens H.A.M., Bantje T.A., Luursema P.B. et al. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007; 132: 1493–1499.
Review
For citations:
Avdeev S.N., Nuralieva G.S., Chuchalin A.G. Efficacy and safety of short-acting anticholinergics in patients with acute exacerbation of chronic obstructive pulmonary disease receiving maintenance therapy with tiotropium. PULMONOLOGIYA. 2008;(1):62-68. (In Russ.) https://doi.org/10.18093/0869-0189-2008-0-1-62-68
Views:
348
Email this article 